Does the media favor CRMD or MIST?

In the previous week, CorMedix had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Milestone Pharmaceuticals. CorMedix's average media sentiment score of 0.00 equaled Milestone Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MIST or DSGN more profitable?

Design Therapeutics' return on equity of -33.07% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% Design Therapeutics N/A -33.07% -31.29%

Does the media refer more to MIST or TLRY?

In the previous week, Tilray Brands had 15 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 16 mentions for Tilray Brands and 1 mentions for Milestone Pharmaceuticals. Tilray Brands' average media sentiment score of 0.50 beat Milestone Pharmaceuticals' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tilray Brands 6 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRME or MIST?

In the previous week, Prime Medicine had 4 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Prime Medicine and 1 mentions for Milestone Pharmaceuticals. Prime Medicine's average media sentiment score of 0.00 equaled Milestone Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACRS or MIST?

In the previous week, Aclaris Therapeutics had 14 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 15 mentions for Aclaris Therapeutics and 1 mentions for Milestone Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 1.25 beat Milestone Pharmaceuticals' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Milestone Pharmaceuticals (MIST) Competitors

$1.23 0.00 (0.00%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$1.25 +0.02 (+1.22%)

As of 04:14 AM Eastern

Compare

MIST vs. CRMD, DSGN, TLRY, PRME, and ACRS

Should you buy Milestone Pharmaceuticals stock or one of its competitors? MarketBeat compares Milestone Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Milestone Pharmaceuticals include CorMedix (CRMD), Design Therapeutics (DSGN), Tilray Brands (TLRY), Prime Medicine (PRME), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Milestone Pharmaceuticals compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

CorMedix presently has a consensus price target of $15.00, suggesting a potential upside of 75.64%. Milestone Pharmaceuticals has a consensus price target of $7.25, suggesting a potential upside of 489.43%. Given Milestone Pharmaceuticals' higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

CorMedix has a net margin of 45.25% compared to Milestone Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

CorMedix has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.15	$163.05M	$2.13	4.01
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A

34.2% of CorMedix shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CorMedix has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

In the previous week, CorMedix had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Milestone Pharmaceuticals. CorMedix's average media sentiment score of 0.00 equaled Milestone Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CorMedix beats Milestone Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Design Therapeutics?

Milestone Pharmaceuticals (NASDAQ:MIST) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Milestone Pharmaceuticals currently has a consensus price target of $7.25, suggesting a potential upside of 489.43%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 57.74%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Milestone Pharmaceuticals has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 1 mentions for Milestone Pharmaceuticals and 0 mentions for Design Therapeutics. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score.

Company	Overall Sentiment
Milestone Pharmaceuticals	Neutral
Design Therapeutics	Neutral

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Design Therapeutics' return on equity of -33.07% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Design Therapeutics	N/A	-33.07%	-31.29%

Milestone Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market.

Summary

Milestone Pharmaceuticals beats Design Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Tilray Brands?

Milestone Pharmaceuticals (NASDAQ:MIST) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, Tilray Brands had 15 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 16 mentions for Tilray Brands and 1 mentions for Milestone Pharmaceuticals. Tilray Brands' average media sentiment score of 0.50 beat Milestone Pharmaceuticals' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tilray Brands	6 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Milestone Pharmaceuticals has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Tilray Brands	-156.51%	-3.31%	-2.42%

Milestone Pharmaceuticals presently has a consensus target price of $7.25, suggesting a potential upside of 489.43%. Tilray Brands has a consensus target price of $11.50, suggesting a potential upside of 128.63%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Milestone Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

Milestone Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A
Tilray Brands	$821.31M	0.71	-$2.19B	-$13.65	N/A

Summary

Milestone Pharmaceuticals beats Tilray Brands on 9 of the 16 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Milestone Pharmaceuticals has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	115.47	-$201.14M	-$1.23	N/A
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Prime Medicine had 4 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 5 mentions for Prime Medicine and 1 mentions for Milestone Pharmaceuticals. Prime Medicine's average media sentiment score of 0.00 equaled Milestone Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prime Medicine presently has a consensus price target of $7.65, suggesting a potential upside of 158.45%. Milestone Pharmaceuticals has a consensus price target of $7.25, suggesting a potential upside of 489.43%. Given Milestone Pharmaceuticals' higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Milestone Pharmaceuticals has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Prime Medicine's return on equity of -188.82% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Summary

Prime Medicine and Milestone Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Aclaris Therapeutics currently has a consensus price target of $11.50, indicating a potential upside of 163.76%. Milestone Pharmaceuticals has a consensus price target of $7.25, indicating a potential upside of 489.43%. Given Milestone Pharmaceuticals' higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Milestone Pharmaceuticals has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	77.77	-$64.92M	-$0.56	N/A
Milestone Pharmaceuticals	$1.55M	98.80	-$63.06M	-$0.68	N/A

In the previous week, Aclaris Therapeutics had 14 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 15 mentions for Aclaris Therapeutics and 1 mentions for Milestone Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 1.25 beat Milestone Pharmaceuticals' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclaris Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Milestone Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

Summary

Aclaris Therapeutics beats Milestone Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Milestone Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIST vs. The Competition

Export

Metric	Milestone Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$153.13M	$3.34B	$6.48B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	-1.81	18.61	23.69	23.74
Price / Sales	98.80	296.61	513.81	108.85
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	3.15	8.04	10.41	6.78
Net Income	-$63.06M	$23.89M	$3.57B	$337.51M
7 Day Performance	-6.82%	-3.28%	0.28%	-2.34%
1 Month Performance	-35.94%	2.78%	3.27%	1.88%
1 Year Performance	-29.71%	36.03%	22.25%	25.55%

Milestone Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIST Milestone Pharmaceuticals	2.1622 of 5 stars	$1.23 flat	$7.25 +489.4%	-28.9%	$153.13M	$1.55M	N/A	30	Gap Up
CRMD CorMedix	2.6014 of 5 stars	$8.45 +0.1%	$15.00 +77.5%	-38.9%	$662.13M	$311.71M	3.97	30
DSGN Design Therapeutics	2.1367 of 5 stars	$10.44 -0.4%	$16.50 +58.0%	+160.8%	$654.55M	N/A	N/A	40
TLRY Tilray Brands	3.5287 of 5 stars	$5.49 -0.4%	$11.50 +109.5%	+24.0%	$642.19M	$210.48M	N/A	2,842
PRME Prime Medicine	1.7022 of 5 stars	$3.40 -4.2%	$7.65 +125.0%	N/A	$641.19M	$4.63M	N/A	N/A	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIST) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. CRMD, DSGN, TLRY, PRME, and ACRS

How does Milestone Pharmaceuticals compare to CorMedix?

Summary

How does Milestone Pharmaceuticals compare to Design Therapeutics?

Summary

How does Milestone Pharmaceuticals compare to Tilray Brands?

Summary

How does Milestone Pharmaceuticals compare to Prime Medicine?

Summary

How does Milestone Pharmaceuticals compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. CRMD, DSGN, TLRY, PRME, and ACRS

How does Milestone Pharmaceuticals compare to CorMedix?

Do analysts prefer CRMD or MIST?

Is CRMD or MIST more profitable?

Which has preferable valuation and earnings, CRMD or MIST?

Do insiders & institutionals believe in CRMD or MIST?

Which has more risk & volatility, CRMD or MIST?

Does the media favor CRMD or MIST?

Summary

How does Milestone Pharmaceuticals compare to Design Therapeutics?

Do analysts recommend MIST or DSGN?

Which has preferable earnings & valuation, MIST or DSGN?

Does the media favor MIST or DSGN?

Do institutionals & insiders hold more shares of MIST or DSGN?

Is MIST or DSGN more profitable?

Which has more volatility & risk, MIST or DSGN?

Summary

How does Milestone Pharmaceuticals compare to Tilray Brands?

Does the media refer more to MIST or TLRY?

Do insiders & institutionals hold more shares of MIST or TLRY?

Is MIST or TLRY more profitable?

Do analysts recommend MIST or TLRY?

Which has more risk and volatility, MIST or TLRY?

Which has better valuation & earnings, MIST or TLRY?

Summary

How does Milestone Pharmaceuticals compare to Prime Medicine?

Which has better earnings and valuation, PRME or MIST?

Do insiders and institutionals hold more shares of PRME or MIST?

Does the media refer more to PRME or MIST?

Do analysts prefer PRME or MIST?

Which has more risk & volatility, PRME or MIST?

Is PRME or MIST more profitable?

Summary

How does Milestone Pharmaceuticals compare to Aclaris Therapeutics?

Do analysts recommend ACRS or MIST?

Which has better valuation and earnings, ACRS or MIST?

Does the media prefer ACRS or MIST?

Which has more risk & volatility, ACRS or MIST?

Do insiders and institutionals have more ownership in ACRS or MIST?

Is ACRS or MIST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools